BRIEF-Agomab Announces First Patient Dosed In Global Nov-Era Phase 2B Study Of Ontunisertib In Fibrostenosing Crohn's Disease
Reuters2026/10/13 20:14Agomab Therapeutics NV AGMB.O:
AGOMAB ANNOUNCES FIRST PATIENT DOSED IN GLOBAL NOV-ERA PHASE 2B STUDY OF ONTUNISERTIB IN FIBROSTENOSING CROHN'S DISEASE
AGOMAB THERAPEUTICS NV - NOV-ERA PHASE 2B STUDY EXPECTED TO ENROLL ABOUT 320 PATIENTS GLOBALLY
Source text: ID:nGNX31Vcl9
Further company coverage: AGMB.O
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Bitcoin ETF assets fall to three-month low as 2026 net outflows top $2.5B
US Pending Home Sales Hit a Record Low. Why That Could Help Bitcoin and Stocks
CoinShares CEO Blames AI for Bitcoin’s Slide, but AI Stocks Are Falling Too

Canadian Dollar underperforms against US Dollar amid hawkish Fed rhetoric
